Information Provided By: 
Fly News Breaks for July 12, 2017
OCLR
Jul 12, 2017 | 10:29 EDT
Cowen analyst Ken Cacciatore said the CRL Ocular received related to Dextenza's manufacturing process is disappointing, but is hopeful the issue will be resolved within the next year. At current levels, Cacciatore believes patient investors will eventually be rewarded for the OTX-TP glaucoma opportunity and reiterates his Outperform rating and $60 price target on shares.
News For OCLR From the Last 2 Days
There are no results for your query OCLR
